- FDA Approves Tykerb for Advanced, Metastatic Breast Cancer
- TODAY | Forbes | GlaxoSmithKline said the U.S. FDA has granted marketing approval for its breast cancer pill Tykerb. more
- For Booming Biotech Firms, a New Threat: Generics
- TODAY | The Wall Street Journal | The future of the biotechnology industry may lie in a steel-and-glass research center a few miles from the red-roofed medieval buildings of the Croatian capital, Zagreb. more
- Biotech Interests Give FDA an Earful Over Regulations
- Mar 12 | San Jose Business Journal | Companies in Silicon Valley and around the country that are pioneering personalized medicine are anxiously awaiting new regulations from the FDA that could change the way they do business. more
- Researchers Say FDA Increases Public Risks By Delaying Safety Data Release
- Mar 09 | The Boston Globe | Heart problems that pushed the painkillers Bextra and Vioxx off the market could have come to light earlier had federal regulators given outside researchers speedier access to raw safety data, according to a commentary written by Boston researchers. more
- Refining Data Mining
- Mar 08 | The RPM Report The FDA and pharmas are taking control of a powerful new tool for drug safety analysis. But there are concerns. more
- Analysis: New Call for FDA Openness
- Mar 07 | UPI | Two researchers Tuesday urged a change in FDA policies to allow the scientific community access to pharmaceutical manufacturers' clinical trial data in order to help reveal safety issues with new drugs. more
- Embattled FDA Chief Fights Back
- Mar 07 | Houston Chronicle | Acting FDA Commissioner Andrew von Eschenbach, who has twice beaten back cancer, is facing another challenge as he struggles to right the ship at the tempest-tossed Food and Drug Administration. more
Feeds